Immunic posted a Q2 net loss of $34.1 million, or $0.80 per share, versus a net loss of $26.8 million, or $2.03 per share, a year earlier.
Operating expenses rose to $35.3 million, including $7.2 million of non-cash stock-based compensation.
Development timeline
Phase 3 ENSURE relapsing MS top-line data is expected by end-2026, with a planned U.S. NDA filing in mid-2027 if positive.
Expense trends and cash position
R&D expense increased to $25.9 million from $21.3 million, driven by higher personnel costs and drug-drug interaction studies supporting a potential NDA.
G&A expense climbed to $9.4 million from on higher personnel, legal and consultancy, and pre-commercial marketing costs.
IMUX•
